Announcements
- Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
- Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
- Microbot Medical Shares Status Following Recent Geopolitical Events
- Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
- Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
- Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
- Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
- Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.50 |
---|---|
High | 0.50 |
Low | 0.50 |
Bid | 0.468 |
Offer | 0.486 |
Previous close | 0.50 |
Average volume | -- |
---|---|
Shares outstanding | 14.40m |
Free float | 14.16m |
P/E (TTM) | -- |
Market cap | 14.40m USD |
EPS (TTM) | -0.8926 USD |
Data delayed at least 15 minutes, as of Sep 05 2018.
More ▼